Literature DB >> 498169

Pharmacology of intravenous melphalan in patients with multiple myeloma.

L Brox, L Birkett, A Belch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 498169     DOI： 10.1016/s0305-7372(79)80007-9

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  10 in total

1.  The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma.

Authors:  U Loos; E Musch; M Engel; J H Hartlapp; E Hügl; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Pharmacokinetics of high dose melphalan.

Authors:  M R Hersh; T M Ludden; J G Kuhn; W A Knight
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

3.  Melphalan estimation by quantitative thin-layer chromatography. Observations on melphalan hydrolysis in vitro and pharmacokinetics in rabbits.

Authors:  I A Taha; R A Ahmad; H J Rogers
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

4.  Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma.

Authors:  A G Bosanquet; E D Gilby
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

5.  Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis. Report in 26 cases.

Authors:  C Ardiet; B Tranchand; P Biron; P Rebattu; T Philip
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

6.  Renal clearance and protein binding of melphalan in patients with cancer.

Authors:  P A Reece; H S Hill; R M Green; R G Morris; B M Dale; D Kotasek; R E Sage
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

7.  Pharmacokinetics of melphalan in children following high-dose intravenous injection.

Authors:  I A Taha; R A Ahmad; D W Rogers; J Pritchard; H J Rogers
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

8.  Plasma melphalan and prednisolone concentrations during oral therapy for multiple myeloma.

Authors:  I A Taha; R A Ahmad; H Gray; C I Roberts; H J Rogers
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

9.  Increasing the effective concentration of melphalan in experimental rat liver tumours: comparison of isolated liver perfusion and hepatic artery infusion.

Authors:  A Marinelli; J H van Dierendonck; G M van Brakel; H Irth; P J Kuppen; U R Tjaden; C J van de Velde
Journal:  Br J Cancer       Date:  1991-12       Impact factor: 7.640

10.  Clinical correlates of in vitro drug sensitivities of ovarian cancer cells.

Authors:  L Morasca; E Erba; M Vaghi; C Ghelardoni; C Mangioni; C Sessa; F Landoni; S Garattini
Journal:  Br J Cancer       Date:  1983-07       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.